State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China.
Department of Gastrointestinal Surgery, The Sixth Affiliated Hospital of Wenzhou Medical University & Lishui City People's Hospital, Lishui 323000, China.
Nutrients. 2022 Oct 11;14(20):4220. doi: 10.3390/nu14204220.
As the largest "immune organ" of human beings, the gut microbiota is symbiotic and mutually beneficial with the human host, playing multiple physiological functions. Studies have long shown that dysbiosis of gut microbiota is associated with almost all human diseases, mainly including type II diabetes, cancers, neurodegenerative diseases, autism spectrum disorder, and kidney diseases. As a novel and potential biological medicine for disease prevention, intervention and drug sensitization, the gut microbiota has attracted more and more attention recently. Although the gut microbiota is a comprehensive microbial community, several star bacteria have emerged as possible tools to fight against various diseases. This review aims to elucidate the relevance of gut microbiota dysbiosis with disease occurrence and progression, and mainly summarizes four well-known genera with therapeutic and sensitizing potential, , , and , thoroughly elucidate their potential value as biological drugs to treat diverse disease.
作为人类最大的“免疫器官”,肠道微生物群与人类宿主共生互利,发挥多种生理功能。研究早就表明,肠道微生物群失调与几乎所有人类疾病都有关,主要包括 2 型糖尿病、癌症、神经退行性疾病、自闭症谱系障碍和肾脏疾病。作为一种新型的潜在生物医学疾病预防、干预和药物增敏手段,肠道微生物群最近引起了越来越多的关注。尽管肠道微生物群是一个综合的微生物群落,但几种明星细菌已成为对抗各种疾病的可能工具。本综述旨在阐明肠道微生物群失调与疾病发生和进展的相关性,并主要总结了具有治疗和增敏潜力的四个知名属, 、 、 、 ,深入阐明它们作为治疗多种疾病的生物药物的潜在价值。